Fludarabine Combined With Either Alemtuzumab or Rituximab in Treating Patients With Refractory or Relapsed B-Cell Chronic Lymphocytic Leukemia

NCT00086775 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Leukemia

Interventions

BIOLOGICAL: alemtuzumab
BIOLOGICAL: rituximab
DRUG: fludarabine phosphate

Sponsor

Bayer